Results 161 to 170 of about 7,362 (230)

Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives. [PDF]

Int J Mol Sci
Dziubańska-Kusibab PJ, Jourdan T, Haendler B.   +2 more
europepmc   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, Volume 117, Issue 10, Page 2803-2818, October 2026.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Context matters in PROTAC design: navigating the trade-off between degradation and developability. [PDF]

J Enzyme Inhib Med Chem
Zhang B, Zhang Y, Zhang B, Hu J, Ke C, Wu T, Wei M, Xia J, Wang M, Zhao Q, Tian L, Liang C.   +11 more
europepmc   +1 more source

E3 Ubiquitin Ligases in MASH‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) is a major cause of progressive liver fibrosis and can ultimately lead to cirrhosis and hepatocellular carcinoma (HCC). MASH‐associated liver fibrosis develops through a complex interplay among lipotoxic hepatocyte injury, oxidative and endoplasmic reticulum stress, inflammatory ...
Ah‐Reum Oh, Yelin Jeong, Young Hoon Jung, Young Un Kim, HyunJoon Gi, Do‐Wan Kim, Young Du Choi, Sang Bae Lee, KyeongJin Kim   +8 more
wiley   +1 more source

Computational mapping of productive POI-E3 ligase conformations to guide de novo degrader design: application to WEE1 and PKMYT1 PROTACs. [PDF]

J Cheminform
Nassar H, Schmidt M, Ibrahim HS, Robaa D, Sippl W.   +4 more
europepmc   +1 more source

Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems. [PDF]

Acta Pharmacol Sin
Yao TT, Zhou Z, Wang GJ, Zhu ZY, Li XN.
europepmc   +1 more source

Precision-Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy. [PDF]

Small
Yao H, Zhang Y, Zhao H, Liu M, Liu C, Wang P, Chen W, Guo Z, Xing D, Yang J, Li B, Wang C.   +11 more
europepmc   +1 more source

Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer. [PDF]

Front Immunol
Zhang F, Wang Q, Li M, Wang T, Lei P, Huang T, Wu Z.   +6 more
europepmc   +1 more source

Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside. [PDF]

Breast Cancer Res
Yang Y, Lin Y.
europepmc   +1 more source

Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
An investigation of the tandem Tudor domain (TTD) domain of UHRF1 identified and extensively characterized the local anesthetic hydroxyprocaine as a strong ligand capable of activating related genes such as p53 and also highlighted a new, potentially druggable intramolecular interaction between TTD and UBL.
Efstratios Tsakalidis, Mariangela Giannouli, Ifigeneia Akrani, Anthi Panara, Eleni Katalagarianou, Kyriaki Degaita, Maria Giahou, Konstantina Kyriakou, Maria Routsi, Panagiota Efstathia Nikolaou, Evangelia Tsitsou, Aggeliki Tsoka, Constantinos C. Vorgias, Emmanuel Mikros, Evangelos Gikas, Eleni K. Efthimiadou, Vassilios Myrianthopoulos   +16 more
wiley   +1 more source